Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating

Cytokinetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $84.00 price target.

Serge Belanger has given his Buy rating due to a combination of factors tied to Cytokinetics’ lead asset, Myqorzo (aficamten), and its market positioning. He highlights that the recent FDA approval for obstructive hypertrophic cardiomyopathy (oHCM), combined with pricing in line with the incumbent therapy Camzyos, supports an attractive commercial opportunity. Importantly, he notes that Myqorzo’s prescribing information and risk management program appear more user-friendly, with no drug–drug interaction monitoring requirement, faster titration with fewer echocardiograms, and a broader left ventricular ejection fraction safety margin, which together should lead to fewer treatment disruptions and make the drug more practical in real-world use.
Belanger also underscores that these clinical and practical advantages position Myqorzo as a potentially safer and more convenient option than Camzyos, enhancing its competitive profile. He raises his price target to $84 from $72, attributing most of the upside to anticipated sales outside the U.S., reflecting confidence in global uptake. Furthermore, he points to the upcoming Phase 3 ACACIA trial readout in non-obstructive HCM (expected in 2Q26) as a pivotal catalyst that could further distinguish Myqorzo, unlock meaningful shareholder value, and spark heightened M&A interest in Cytokinetics. Collectively, these elements underpin his conviction that the risk‑reward remains favorable, justifying a Buy recommendation on CYTK shares.

Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Ocular Therapeutix, and BioCryst. According to TipRanks, Belanger has an average return of 14.2% and a 51.69% success rate on recommended stocks.

In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $88.00 price target.